ReportsnReports - Advances in Ion Channel Drug Discovery

06-Apr-2012 | News-Press Release

Approximately 13% of approved drugs have mechanisms involving the modulation of ion channel activity, which makes ion channels the second-largest mechanistic class of marketed compounds. Currently approved drugs address important disease areas including diabetes, epilepsy, hypertension, cardiac arrhythmia, anxiety, and pain.

Approximately 35% of agents in development have big pharma sponsorship, with the remaining 65% under development by smaller biotech. CNS indications account for 45% of development programs. Agents in late-stage development include several first-in-class agents acting at the cystic fibrosis transmembrane regulator, and new NMDA and AMPA antagonists.

Earlier-stage programs focus on selective Nav blockers (following on from genetic validation of Nav1.7 involvement in pain), subtype-selective NMDA and AMPA blockers, and a large number of TRP family members for a variety of indications.

Features and benefits
• Understand the competitive landscape in ion channel modulation and compare the pipelines of specialist companies operating in this area
• Identify the most promising targets from a “likelihood of success” viewpoint.
• Identify the targets with scope for ion channel intervention and major market opportunity.
• Understand which advances in target discovery, technology, and clinical development will have biggest impact to move the area forward.
• Benchmark available technologies against the gold standard for ion channel discovery.

Request a Sample for or Inquire before buying the report Ion Channel Drug Discovery

Your key questions answered
• Why have ion channels been underexploited and what is changing to enable greater realization of these targets’ potential?
• What disease areas offer further scope for new ion channel modulators, and which are likely to have the best market potential?
• Which companies have the most promising late development candidates?
• Which companies are offering innovative technologies to facilitate the discovery of drugs acting at ion channel targets?
• What challenges remain to be overcome in fully exploiting the possibilities presented by modulation of ion channel targets?

Major points covered in Table of Contents of this report include:
Characteristics of ion channels
Commercial exploitation
Discovery approaches
New opportunities
Specialist company profiles
List of Tables
List of Figures

Browse reports related to Pharmaceuticals @

Priyank Tiwari
TX, Dallas North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: +1-888-391-5441


Show HTML Embed Snippet

This release was submitted by a PRSafe user.
Any communication related to the content of this release should be sent to the release submitter.

Contact Info

From Name
From Email
From Company
Login to Submit Email

Author Info

Tag Cloud


More Releases


Add a Comment